CAS 5623-18-7
:Metfol-B
- 4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]methylamino]benzoic acid
- Benzoic Acid, 4-[[(2-Amino-1,4-Dihydro-4-Oxo-6-Pteridinyl)Methyl]Methylamino]-
- Benzoic acid, 4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]methylamino]-
- Benzoic acid, p-[[(2-amino-4-hydroxy-6-pteridinyl)methyl]methylamino]-
- Metfol-B
- NSC 408937
Ref: 4Z-M-705
5mgPrezzo su richiesta10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiestaN10-Methyl Pteroic Acid
CAS:Impurity Methotrexate EP Impurity D
Applications N10-Methyl Pteroic Acid (Methotrexate EP Impurity D) is a Methotrexate (M260675) impurity D.
References Cramer, S., et al.: Cancer Res. 1984, 44, 1843 (1984), Hendel, J., et al.: Eur. J. Clin. Pharmacol., 26, 103 (1984),Formula:C15H14N6O3Colore e forma:Orange To Dark RedPeso molecolare:326.31N10-Methyl pteroic acid
CAS:N10-Methyl pteroic acid is a novel immunosuppressant that inhibits T-cell proliferation and promotes regression of inflammatory bowel disease. It has been shown to be effective in treating cancer patients, with the terminal half-life being approximately 20 hours. N10-Methyl pteroic acid is a potent inhibitor of human acute lymphoblastic leukemia cells. It can also be used as an immunosuppressant for organ transplantation, with desorption from gels using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF MS) and bioanalytical methods such as high performance liquid chromatography (HPLC).
Formula:C15H14N6O3Purezza:Min. 95%Peso molecolare:326.31 g/molRef: ST-EA-CP-M12004
10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiesta




